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Sumnlary 
Soluble CD23 (sCD23) has multiple IgE-independent biological activities. In the present study, 
we examined the regulatory effect of sCD23 on cytokine production by human peripheral blood 
mononuclear cells (PBMC). We show that sCD23 enhances by about 80-fold the interleukin 
2 (IL-2)-induced interferon 7  (IFN-3')  production and by about 10-fold the response to IL-12. 
This potentiating activity is time and dose dependent and is not associated with a significant 
effect on DNA synthesis.  The sCD23 costimulatory activity for IFN-3' synthesis is drastically 
reduced in monocyte-depleted PBMC, suggesting that monocytes may be the target for sCD23, 
This hypothesis was supported by the following observations.  First, sCD23 alone is a potent 
inducer of tumor necrosis factor a  (TNF-ot) production by PBMC and this effect disappears 
after monocyte depletion. The triggering of TNF-ot release is specifically  inhibited by neutralizing 
anti-CD23 monoclonal antibody (mAb). In addition, IL-2 and IL-12  synergize with sCD23 
to induce TNF-ot production. Second, sCD23 triggers the release of other inflammatory mediators 
such as IL-lot, IL-1/3, and IL-6.  Finally, TNF-a  production in response to IL-2 and sCD23 
precedes IFN-y and IFN-3' secretion is significantly inhibited by anti-TNF-c~  mAb, indicating 
that the sCD23 costimulatory signal for IFN-y production may be partially mediated by TNF-ot 
release. It is proposed that sCD23 is a proinflammatory cytokine that, in addition, may play 
an important role in the control of the immune response via the enhancement of IFN-N production. 
T 
he CD23 antigen (low affinity receptor for IgE) (FceRII) 
is a 45-kD membrane type II glycoprotein mainly ex- 
pressed on B lymphocytes and monocytes (1). However, it 
can also be found on a variety of hematopoietic cells including 
eosinophils, platelets,  and T  cells (1). Membrane CD23 is 
cleaved by autoproteolysis into soluble forms of various mo- 
lecular sizes (2, 3). Although CD23 and its soluble products 
were demonstrated to be involved in IgE regulation (4, 5), 
most of the activities ascribed to soluble CD23 are pleiotropic 
and IgE independent. These include costimulation with IL-1 
of prothymocyte  maturation (6), myeloid precursor cell growth 
(7), prevention of apoptosis of germinal center B cells (8), 
and increase of histamine release by human basophils (9). The 
last two activities  are shared by some anti-CD21 mAbs (8, 
9), inasmuch as CD21 is reported to be a novel ligand for 
CD23 (10). 
IL-4 and, more recently, IL-13,  are the most potent in- 
ducers of CD23 and sCD23 in B cells (11, 12). In addition 
to IL-4, both IL-3 and GM-CSF increase CD23 expression 
and sCD23 release by human monocytes (13). IFN-y modu- 
lates CD23 expression by inhibiting the IL-4-induced CD23 
expression  on B cells (11). On monocytes, IFN-3' induces 
sCD23 release, whereas its effects on surface CD23 expres- 
sion is still debated (14-16).  In the studies presented here, 
we investigated the regulatory activities  of soluble CD23 
(sCD23) 1 on cytokine production by unfractionated PBMC. 
We demonstrate that sCD23 costimulates IL-2 or IL-12- 
induced IFN-3' production and directly triggers TNF-ot, 
IL-lot, IL-13, and IL-6 release by human PBMC. 
Materials and Methods 
Reagents.  Human recombinant IL-2 was kindly provided by 
Dr. D. Bron (Institut Bordet, Brussels, Belgium). Human recom- 
binant IL-12 was a generous gift from Dr. M. Gately (Hoffmann- 
La Roche, Nutley, NJ). Affinity-purified  recombinant  sCD23, mAb 
to CD23 (clone 63), and class-matched control mAbs were pre- 
pared in our laboratory (17, 18). Neutralizing anti-TNF-o~ mAb 
was purchased from 1~ & D Systems,  Inc. (Minneapolis,  MN). All 
mAbs, cytokines, media, and additives contained low endotoxin 
levels (<15 pg/ml) as determined  by the chromogenic  Limulus ame- 
bocyte lysate (QCL-1000; BioWhittaker, Inc., Walkersville, MD). 
I Abbreviation used in this paper: sCD23,  soluble CD23. 
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density gradient centrifugation  of heparinized blood using Lym- 
phoprep  (Nycomed,  Oslo,  Norway).  Monocyte depletion  was 
achieved with  anti-CD14  (Becton Dickinson  & Co.,  Mountain 
View, CA)-coated goat anti-mouse IgG Dynabeads (Dynal, Oslo, 
Norway). PBMC and monocyte-depleted PBMC were cultured in 
quadruplicate  at  106/ml in  96-well flat-bottomed  Falcon plates 
(Becton  Dickinson, Lincoln Park, NJ) in complete serum-free  HB101 
medium (GIBCO BRL, Gaithersburg, MD) supplemented with 
2 mM glutamine,  1 mM sodium pyruvate, 10 mM Hepes, 100 IU 
penicillin, and 100/~g/ml streptomycin. For proliferation assay, cells 
were  pulsed  with  0.5  #Ci  [3H]thymidine  (Amersham  Corp., 
Arlington Heights,  IL) during the last 6 h of the culture period 
and  [3H]thymidine  incorporation  was  measured by a standard 
liquid scintillation  counter.  For TNF-c~, IL-I~,  IL-1/3, and IL-6 
production,  cultures  were  performed  at  106/ml in  5-ml sterile 
Falcon tubes  (Becton Dickinson). 
Lymphokine Determinations,  IFN-7 was measured by two-site 
solid-phase RIA using anti-IFN-7 mAb (clone 42.25) to coat the 
solid  phase and  125I-labeled anti-IFN-3,  mAb  (clone  KM48, 
provided by Dr. S. Alkan, Ciba-Geigy, Basel, Switzerland) as de- 
tecting probe. The cytokine-specific ELISA and their sensitivities 
were: IL-lot (3.9 pg/ml), IL-1/3 (3.9 pg/ml), and IL-6 (4.6 pg/ml) 
(R & D Systems, Inc.). TNF-ot was assessed using a sandwich ELISA 
employing mouse mAb to human TNF-c~ (clone T144.B, kindly 
given by Dr. T. Nakajima, St. Mariana University School of Medi- 
cine, Kawasaki, Japan) and a polyclonal rabbit anti-TNF-ot anti- 
body received from Dr. J.  Tavernier (Roche Research Institute, 
Ghent, Belgium). The assay was calibrated against the TNF-c~ stan- 
dard obtained from the National Institute of Biological Standards 
and Control (Hertfordshire, England). The limit of detection for 
the TNF-~ ELISA was  150 pg/ml. 
Results 
sCD23  Enhances IFN-9,  Production.  To  determine  the 
regulatory effects of sCD23 on IFN-3, production, normal 
human PBMC were stimulated for 3 d with either IL-2 or 
IL-12 in the presence of sCD23. As shown in Fig. 1, sCD23 
strongly  increases  by  'x,80-fold  the  IL-2-induced  IFN-3, 
production and enhances by *10-fold the response to IL-12. 
Of note,  sCD23 alone is unable to induce IFN-y produc- 
tion. The costimulatory activity of sCD23 is observed at var- 
ious cytokine concentrations ranging from 25 to 500 U/ml 
for IL-2 (Fig. 2), and from 10 to 60 pM for IL-12 (data not 
shown)  suggesting  that  sCD23  lowers  the  threshold  for 
cytokine-induced IFN-y production by PBMC. To further 
investigate the regulation of IFN-3, production by sCD23, 
we examined the effect of  varying the stimulation period and 
titrating the concentrations of sCD23. Time course analysis 
showed that the sCD23 potentiating activity is already ob- 
served at day i  (mean  +  SD of three separate experiments: 
228  _+  8 U/ml of IFN-3, in treated vs 8.6  _+  3.2 U/ml in 
untreated cultures) reaching plateau at day 5 (Fig. 3). sCD23 
costimulates IFN-3' secretion in a dose-dependent manner 
(Fig. 4). Its effect is significant at 3 ng/ml whereas optimal 
enhancement of IFN-3, production is observed at concentra- 
tions between 25 and 50 ng/ml (data not shown). These data 
also indicate that sCD23 has little or no effect on IL-2- or 
IL-12-induced DNA synthesis strongly suggesting that the 
increase in IFN-3, production is not related to cell prolifera- 
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Figure  1.  sCD23  increases IL-2-  or IL-12-induced  IFN-3, production. 
(A) PBMC were  cultured with or without IL-2 (25 U/ml) or sCD23 (25 
ng/ml) and in the presence  of IL-2 plus sCD23. (/3) PBMC were  cultured 
with or without IL-12  (40 pM) and in the presence  of IL-12 plus sCD23 
(25 ng/ml). After 3 d, IFN-y was measured  in the culture supernatants. 
Data represent mean _+  SD of (A) 15 and (B) 11 experiments. 
tion. Indeed, sCD23 augments the IL-2-induced steady state 
IFN-3, mRNA level  (data not shown). 
sCD23 Triggers TNF-cr, IL-1, and IL-6 Release  The effector 
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Figure 2.  sCD23  lowers the threshold  of IL-2-induced  IFN-3,  produc- 
tion. PBMC were cultured for 2 d with titrated concentrations of I].-2 
(5-1,000 U/ml) in the absence  (O) or presence  (@) of sCD23 (25 ng/ml). 
IFN-3, was measured in culture supernatants. Data are representative  of 
three experiments. 
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Figure  3.  Kinetics  of sCD23  enhancement  of IL-2-induced  IFN-3' 
production.  PBMC were cultured in medium alone (11), II.-2 (25 U/ml) 
(O), or IL-2 plus sCD23 (25 ng/ml) (A), and culture supernatants were 
collected  at the indicated times and assessed for IFN-',/content.  Data are 
representative of three experiments. 
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reported to be T and NK cells (19). However, this response 
is enhanced by monocyte-derived cytokines such as TNF-a 
and IL-1 (20-22). We therefore examined whether the pres- 
ence of monocytes was required for sCD23 to increase IFN-'y 
by PBMC. The results in Table 1, show that monocyte deple- 
tion strongly reduces sCD23  ability  to costimulate IFN-y 
production. Most interestingly, these data indicate that sCD23 
alone is a potent inducer of TNF-o~ secretion by PBMC. The 
absence of detectable amounts of TNF-ot in monocyte-depleted 
PBMC suggests that the sCD23-induced TNF-ot is largely 
derived from monocytes. The triggering of TNF-u release 
is time and dose dependent (Fig.  5 A)  and specific (Fig.  5 
B).  Indeed,  the TNF-ot production in response  to sCD23 
alone  or sCD23  and IL-2 is completely abolished by neu- 
tralizing anti-CD23 mAb with no effect of isotype-matched 
control mAb (Fig. 5 B). We next performed kinetic studies 
and showed that TNF-ot secretion  in response  to IL-2 and 
sCD23  precedes  IFN-'y  production  suggesting  that  the 
sCD23-induced TNF-ot secretion by monocytes may partially 
mediate the costimulatory signal for PBMC IFN-3' produc- 
tion (Fig. 6 A). This hypothesis is supported by the observa- 
tions that neutralizing anti-TNF-ot mAb significantly decreases 
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Figure  4.  Dose-dependent effect of sCD23 on IL-2- or IL-12-induced 
IFN-y production and proliferation.  PBMC were incubated for 3 d with 
(A) IL-2 (25 U/ml) or (B) IL-12 (40 pM) and titrated concentrations  of 
sCD23. Culture supernatants were collected  and assessed for IFN-3' con- 
tent (11),  and [3H]thymidine uptake was measured as described (0). Data 
represent mean +  SD of quadruplicate samples and are representative of 
three experiments. 
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Figure  5.  sCD23  specifically induces TNF-~  production.  (A) PBMC 
were cultured for 5  or 20 h  with titrated concentrations  of sCD23  and 
cell-free supernatants were tested for TNF-c~ release. Data are representa- 
tive of two experiments.  (/3) PBMC were cultured for 20 h in the absence 
or presence of sCD23  (25  ng/ml),  IL-2 (25 U/ml),  or IL-2 and sCD23. 
Some  cultures were supplemented  with  30/xg/ml of neutralizing  anti- 
CD23  mAb or isotype-matched  control mAb.  Data are representative of 
five separate experiments. 
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TNF-cx  IFN-"/ 
(ng/ml)  (U/ml) 
Monocyte-depleted  Monocyte-depleted 
Stimulus  PBMC  PBMC  PBMC  PBMC 
Exp 1  Exp 2  Exp 1  Exp 2  Exp 1  Exp 2  Exp  1  Exp 2 
Nil  <0.15  <0.15  <0.15  <0.15  <10  <10  <10  <10 
sCD23  1.75  0.51  <0.15  <0.15  <10  <10  <10  <10 
IL-2  <0.15  0.27  <0.15  <0.15  72  94  26  <10 
IL-2  +  sCD23  1.97  0.90  <0.15  <0.15  2958  3374  236  64 
PBMC or monocyte-depleted  PBMC were cultured in the absence or presence of sCD23 (25 ng/ml), IL-2 (25 U/ml), or IL-2 and sCD23. TNF-ot 
and IFN-T production were measured in culture supernatants after 20 h and 3 d, respectively. 
the IL-2 and sCD23-induced IFN-'y production (Fig. 6 B). 
Finally, we determined whether sCD23 triggers the release 
of other inflammatory mediators by PBMC.  As illustrated 
in Table 2, sCD23 induces significant amounts of IL-lot, IL- 
13, and IL-6 with no additive effect in the presence of IL-2 
or IL-12. However, it synergizes with IL-2 ([mean  •  SEM] 
1.33  _+  0.24 vs. 0.85  +  0.15,  n  =  25, p <0.001)or IL-12 
(1.61  _+  0.46 vs. 0.88  +  0.23, n  --  14, p <0.05) to further 
enhance TNF-ot production. 
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Figure 6.  IFN-T  production  by PBMC stimulated  with II-,2  and sCD23 
is partially mediated by TNF-ot release. (-4) PBMC were cultured with 
IL-2 (25 U/ml) and sCD23 (25 ng/ml) and culture supernatants were  col- 
lected at the indicated times and assessed for TNF-~ (0) or IFN-'y ([]). 
Data are representative  of two experiments.  (B) PBMC were  cultured  with 
IL-2 (25 U/ml) and sCD23 (25 ng/ml) in the presence  of  anti-TNF-~ mAb 
or isotype-matched  control  mAb (10 #g/ml) and culture  supernatants  were 
tested for IFN-3'  production. Data are representative  of  three  experiments. 
Discussion 
In the present study, we first report that sCD23 provides 
a potent costimulus for PBMC IFN-y production in the pres- 
ence of IL-2 or IL-12.  This potentiating activity is time and 
dose dependent, and is observed at low IL-2 concentrations. 
The IFN-3' expression is limited to two normal cell types, 
T  and NK cells (19). Physiological activation of T lympho- 
cytes to induce cytokine production, including IFN-%  re- 
quires TCR occupancy and APC-derived costimulatory signals 
(23). More precisely, monocytes are reported to enhance IFN-q/ 
synthesis by mitogen-stimulated T  cells via direct cell-cell 
contact involving CD2 signaling (24). However, IL-1 (20) 
or TNF-ot (21) in synergy with IL-2 may partially replace 
the monocyte-mediated IFN-'y production signal.  Similarly, 
IFN-'y production by stimulated SCID splenocytes (NK cells) 
required TNF-ot synthesis (22).  In this SCID model, IL-2 
was synergistic with IL-12 or IL-12 plus TNF-cz to induce 
IFN-%' release,  but not with TNF-ot alone (25). 
In agreement with the above studies, our results indicate 
that the enhancement of IFN-y by sCD23 largely depends 
on the presence of monocytes. Furthermore, we show that 
sCD23 synergizes with IL-2 and IL-12 to induce TNF-o~ re- 
lease and that this effect completely disappears upon selective 
monocyte depletion. Taken together, it is tempting to specu- 
late that the sCD23 costimulatory activity for IFN-'y produc- 
tion is mediated by TNF-ot release and that monocytes are 
the target for sCD23 and the source of TNF-ot production. 
This hypothesis is supported by the observations that TNF-c~ 
production precedes IFN-y secretion and that neutralizing 
anti-TNF-ot mAb partially inhibits the IL-2- and sCD23- 
induced IFN-y production. It should be mentioned that NK 
cells are also  capable of producing TNF-ot (26). 
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Stimulus  TNF-c~  IL-la  IL-I~/  IL-6 
n  g /ml  pg  /ml  pg  /ml  pg  /ml 
Nil  (0.15  (3.9  (3.9  25  _+  0.7 
sCD23  2.1  _+  0.95  211  _+  16  182  _+  41  645  _+  24 
IL-2  (0.15  12  __  11  73  _+  75  179  +_  53 
IL-2  +  sCD23  3.62  _+  0.9  378  _+  41  149  _+  8.5  613  _+  27 
IL-12  (0.15  12  _+  16  125  _+  168  123  +  91 
IL-12  +  sCD23  4.6  _+  2.0  347  +  3  154  _+  13  724  +  31 
PBMC were cultured for 20 h with sCD23 (25 ng/ml), IL-2 (25 U/ml), IL-12 (40 pM), or sCD23 and IL-2 or IL-12. Culture supernatants were 
harvested for cytokine  determination  as described. Data are the mean _+ SD of two experiments. 
We next demonstrate that sCD23 is a proinflammatory 
cytokine inasmuch as sCD23 alone directly triggers TNF-ol, 
IL-lc~, IL-1B, and IL-6 release by PBMC. The sCD23-induced 
TNF-o~ occurs rapidly (already  detectable after 5 h) and is 
specific since neutralizing anti-CD23 mAb abolishes sCD23 
or IL-2 and sCD23-induced TNF-c~ production. Although 
monocytes release TNF-a and IL-1 after stimulation with 
endotoxin, PMA or gram-positive bacterial components, some 
more physiological triggers have been described such as LFA-3, 
CD44,  and CD45  engagement (27).  Alderson et al.  (28), 
recently reported that CD40L-transfected cells costimulated 
TNF-c~  production by purified monocytes in the presence 
of GM-CSF, IL-3, or IFN-% Finally, ligation of membrane 
CD23 on IL-4-treated monocytes by anti-CD23 mAb (29) 
or by IgE-immune complexes (30)  triggers inflammatory 
mediator release, further suggesting that the CD23 Ag may 
be considered as a proinflammatory molecule. Of note, and 
in agreement with our previous report (29), anti-CD23 mAb 
alone does not trigger inflammatory mediator release in un- 
stimulated monocytes (Fig.  5 B). 
The present observations that the costimulus provided by 
sCD23 for PBMC IFN-~/and TNF-o~ production disappears 
after monocyte depletion and that sCD23 alone is a potent 
inducer of inflammatory mediators  strongly suggest that 
monocytes express a ligand for CD23. In addition to the well- 
established  IgE molecule, CD21 has been proposed to serve 
as a second ligand for CD23 (10). However, CD21 Ag is pri- 
marily expressed on B cells and follicular dendritic cells but 
not on monocytes (31). We recently reported (32) that sCD23 
binds to a novel ligand different than IgE and CD21.  Our 
unpublished data indicate that monocytes express this sCD23 
binding molecule, suggesting without demonstrating, that 
this novel ligand may be a functional receptor. 
Whether the in vivo overexpression  of CD23 is involved 
in the increased levels of inflammatory cytokines seen in cer- 
tain disease states  remains to be determined. For instance, 
in patients with rheumatoid arthritis, IL-1, TNF-o~, and GM- 
CSF has been found in synovial fluid (33).  Also,  their sera 
contained elevated levels of serum sCD23 (16 ng/ml in rheu- 
matoid arthritis vs 4.5 ng/ml in control sera) (34). The pos- 
sibility therefore exists that GM-CSF, which has been shown 
to induce CD23 expression  on monocytes (13), may be in- 
volved in the progression of the disease. In that regard, Hellen 
et al. (35), have reported that high CD23 expression in syno- 
vial biopsy from patients with all forms of arthritis may be 
related to the severity of the inflammatory infiltrate. Simi- 
larly, in patients suffering of chronic renal failure, increased 
levels of serum sCD23  were shown to be correlated with 
TNF-ol and IL-6 (36). We hypothesize that T cell and mono- 
cyte activation,  reported  in  this  disease  (36),  reflects  the 
costimulatory activity of sCD23 described in vitro. In addi- 
tion, the activated mononuclear cells may contribute to in- 
creased CD23 expression  inasmuch as activated monocytes 
readily express CD23  (14) and activated T  cells are potent 
inducers of CD23 on B cells (37).  Finally, af~nity-purified 
native sCD23 was reported to induce monophasic fever in 
rabbits, further supporting the present in vitro data that sCD23 
triggers the release of proinflammatory mediators (38). 
IFN-qr and TNF-c~ are two critical molecules that play a 
central role in the macrophage-mediated host defense against 
intracellular pathogens (39).  In addition, IFN-3~ is impor- 
tant in the regulation of physiological processes  including 
Thl development and Ig-class  switch (40).  Therefore, the 
ability of sCD23 to enhance IFN-'y and to trigger TNF-o~ 
production underlines its potential role in the control of the 
immune response. 
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